Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024.

Oxford researchers have developed a single-shot malaria vaccine using programmable microcapsules that release booster doses ...

Novavax is a leading pharmaceutical company dedicated to creating protein-based vaccines for diseases like COVID-19 and malaria. Learn more about their innovative vaccine development process and ...

The results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-MTM) show it is well-tolerated and offers effective protection against the blood-stage of the disease—the first ...

Novavax's fundamental prospects beyond COVID-19, such as its NanoFlu influenza vaccine and R21/Matrix-M malaria vaccine, raise questions about its long-term sustainability. solarseven/iStock via ...

A malaria vaccine developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab has been hailed as a possible game-changer in the fight against the deadly parasitic ...

Trials have shown it to be 79% effective at preventing the disease in young people, and its production capacity and low price give it a "huge advantage" over the only other malaria vaccine, RTS,S ...

Ivory Coast administered the first doses of the world’s second malaria vaccine this week, according to the vaccine’s manufacturers, marking the latest development in a decades-long effort to ...

The malaria vaccine needed this sign-off, and since the European agency, a stringent regulator, had approved it, GSK and PATH assumed the W.H.O. would do so swiftly, too.